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Introduction
Fewer than 50% of schizophrenia patients respond to 
initial treatment with antipsychotic medications [1]. Th is 
is mainly due to the fact that there is not suffi  cient 
understanding of the underlying pathophysiology to aid 
diagnosis or treatment selection [2]. Furthermore, the 
traditional treatment approach usually involves random 
selection and switching of drugs multiple times to 
achieve an adequate response. Th is has resulted in high 
drug attrition and lack of effi  cacy of blockbuster drugs in 
patient subpopulations. Th erefore, reliable tests with a 
biological rationale to guide treatment selection are 
needed. Despite almost a century of research, the 
diagnosis of schizophrenia still relies on the subjective 
assessment of symptoms by clinicians according to classi­
fi cations listed in the Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition, or the International 
Statistical Classifi cation of Diseases and Related Health 
Problems, 10th Revision. Also, current diagnoses are 
biased towards detection of symptoms of psychosis. 
Schizophrenia symptoms are generally classifi ed as 
positive (psychosis, hallucinations, delusions), negative 
(anhedonia, dysphoria, aff ective fl attening) or cognitive 
(low attention, memory, executive functions). However, it 
is not known whether specifi c symptoms are linked to 
defi ned pathophysiologies [3]. As a result, there has been 
a recent shift towards the study and identifi cation of 
molecular biomarkers in psychiatric disorders, using 
techniques such as proteomics [4].
Proteomic techniques can be used as a non­biased 
screening approach and analyses of postmortem brain 
tissues from schizophrenia patients have provided 
insights into the pathways aff ected in the disease. It is 
anticipated that the use of biomarkers identifi ed in these 
studies can lead to improved diagnosis through better 
classifi cation of patients, to more eff ective treatment of 
patients by identifi cation of those who are most likely to 
respond to specifi c medications, and to development of 
more effi  cacious drugs that target the relevant molecular 
pathways.
Recent studies have established a role for neuro­
infl ammation in schizophrenia, as shown by increased 
serum concentrations of pro­infl ammatory cytokines and 
chronic humoral responses [5]. Moreover, proteomic 
studies of postmortem brain tissue have found diff erences 
in immune­related proteins [6]. Schizophrenia has also 
been associated with peripheral manifestations related to 
metabolic or hormonal dysregulation, including dyslipid­
emia, hyperinsulinemia and type 2 diabetes mellitus [7,8]. 
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Although these effects can result from administration of 
antipsychotic medications, they have also been observed 
prior to disease development when no antipsychotics 
were used [8]. Furthermore, proteomic analyses of post­
mortem brain tissues from schizophrenia patients have 
identified effects on proteins involved in regulation of 
neuronal and synaptic function [9­13] and alterations in 
glucose metabolism and insulin signaling pathways [14,15]. 
This suggests a link between the brain and periphery in 
the onset and development of the disease. Likewise, there 
have been reports of hypothalamic­pituitary­adrenal 
(HPA) axis disturbance in schizophrenia, which has been 
linked to abnormal insulin signaling [16,17].
This review will address the study of schizophrenia 
based on differences in proteomic signatures in the 
central nervous system and peripheral tissues related to 
dysregulation in inflammatory, metabolic and hormonal 
pathways. Taken together, these findings suggest the 
presence of distinct molecular endophenotypes as risk 
factors for schizophrenia. We will also review studies that 
have attempted to identify proteomic profiles that can 
predict response to antipsychotic medications. We hope 
to demonstrate that proteomic research can contribute to 
de­convoluting the complexity of schizophrenia, from 
symptom­based concepts to a biological understanding 
for the ultimate application in personalized medicine 
approaches.
The need for proteomics-based biomarkers in 
schizophrenia
The development of biomarkers is constantly advancing 
with the aim of applying these in diagnostic studies and 
clinical trials. Regulatory health authorities such as the 
Food and Drug Administration (FDA) now consider 
biomarkers to be essential in the pharmaceutical industry 
for antipsychotic drug discovery [18]. In line with this, 
they have called for modernization of methods and 
technologies to facilitate the delivery of more efficacious 
and safer drugs [19]. According to the FDA guidance for 
pharmaceutical companies on pharmacogenomic data, 
biomarkers must be categorized into three classes: 
(1) exploratory biomarkers, (2) probable valid bio markers, 
and (3) known valid biomarkers [20]. For the first class, 
there must be scientific evidence. The transition to the 
second class requires that a biomarker can be measured 
in a test system with well­established performance charac­
teristics and that there is established evidence that explains 
the biological, pharmacological, toxicological or clinical 
significance of the results. A biomarker will achieve the 
third class if the results can be replicated in studies 
involving a large number of patients at different sites, 
laboratories or agencies in cross­validation experiments.
One strategy for biomarker qualification that is receiv­
ing increasing interest is through their co­development 
with drugs [21]. This requires that biomarker use is 
limited to applications involving the corresponding drug. 
This approach was first described by the FDA in a white 
paper guidance that stipulated that increased knowledge 
about the biology of a biomarker and a robust association 
between the biomarker signal and the clinical result will 
lead to a more efficient drug development process with a 
higher probability of success [21]. Thus, inclusion of 
biomarkers into the clinical development pipeline will 
only be achieved by a rigorous scientific approach, which 
includes standardized operating procedures for patient 
selection, sample collection, laboratory analysis and data 
processing. Also, early interaction with the appropriate 
regulatory agencies is essential to ensure that studies are 
designed and biomarker tests are carried out appropriately.
However, this is not a simple task. The identification of 
biomarkers for psychiatric disorders is challenging due to 
the overlap of symptoms across different disorders and 
the marked heterogeneity of these symptoms in affected 
individuals. In addition, there is currently a poor 
understanding of the underlying causes of the disease at 
the molecular level. However, emerging proteomic 
platforms have facilitated the identification of biomarker 
candidates by simultaneous measurement of hundreds or 
thousands of molecules in non­hypothesis driven 
profiling studies. It is expected that biomarkers that are 
associated with the disease state or with the mechanism 
of action of psychiatric medications will lead to improved 
diagnosis and pave the way for more effective treatment 
of patients.
Proteomic technologies used in schizophrenia 
research
Early proteomic studies in psychiatry have used two­
dimensional gel electrophoresis followed by mass spec­
tro metry (MS) for comparative global analyses. Develop­
ments in MS instrumentation and techniques have 
allowed the establishment of high­throughput pro teo mic 
techniques. The basic idea of shotgun proteomics is to 
digest the proteome of interest using specific enzymes 
and identify the resulting peptides by sensitive and 
accurate MS analyses. Depending on the complexity of a 
given proteome, pre­fractionation steps may be required 
using techniques such as subcellular fractionation, liquid 
chromatography and gel­based techniques. A range of 
techniques can be used for quantification of shotgun MS 
results, such as in vivo or in vitro stable isotope labeling, 
isobaric tag for relative and absolute quantification, and 
label­free approaches [22]. Shotgun MS­based studies 
[23] and targeted multiplex analyte profiling with the 
Luminex platform [24,25] have yielded molecular tests 
that are being introduced in clinical laboratories for 
routine screening purposes. Luminex is a fluorescent­
bead­based technology that allows the simultaneous 
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measurement of multiple analytes in small volume 
samples. Also, this platform is suitable for further 
develop ment of accurate, sensitive, and specific assays, 
given its ease of use in laboratory and clinical settings. 
The emerging field of mass cytometry [26], which com­
bines the benefits of MS with those of flow cytometry, 
may also bring new insights into biomarkers of schizo­
phrenia at the functional level, with potential personal­
ized applications in the clinic.
Proteomic studies on serum or plasma from schizo­
phrenia patients have mainly revealed changes in proteins 
involved in molecular transport (transthyretin [27], 
apolipoprotein A1 [28]), antioxidant functions (gluta­
thione [29], thioredoxin [30], superoxide dismutase [30]) 
and growth factors (brain­derived neurotrophic factor 
[9]), along with changes in inflammation and hormonal 
signaling that will be described in detail below. Proteomic 
studies of postmortem brain tissues in psychiatry have 
identified effects on proteins involved in cellular struc­
ture and transport [10], metabolism [11] and synaptic 
function [12,13], along with several proteins that are also 
found in serum or plasma, as described above [31]. This 
suggests that similar pathways might be affected in both 
the brain and the periphery. However, few of these 
findings in the brain have been validated and most would 
be difficult to develop as clinically useful assays due to 
the inaccessibility of the tissue. The majority of the 
published studies have used western blot and immuno­
assay­based methods for validation, which are both depen­
dent on availability of high­affinity and high­specificity 
antibodies. Other validation methods, such as selective 
reaction monitoring, have only been used recently in 
psychiatry [32]. As mentioned in the previous section, in 
order for a biomarker to achieve clinical status, it is 
essential that candidates can be cross­validated in large 
patient cohorts at multiple clinical centers using well­
established measurement systems [20,21].
Biomarker candidates related to inflammation
Multiplex immunoassay profiling using cytokine arrays 
have identified increased levels of IL­1β in cerebrospinal 
fluid in first­episode schizophrenia patients, suggestive of 
immune system activation in brain tissue in some 
patients [33]. This is consistent with studies showing that 
brain development can be affected by alterations in the 
balance between pro­inflammatory and anti­inflamma­
tory cytokines [34,35]. Furthermore, these immune altera­
tions have been linked to glutamatergic hypofunction, 
which in turn has been linked to schizophrenia patho­
physiology. Transcriptomic and proteomic profiling of 
schizophrenia postmortem brains have identified increased 
levels of inflammation­related genes and proteins in 
oligodendrocytes and endothelial cells, which are known 
to be regulated by the proinflammatory cytokines 
TNF­α, IFN­α and IFN­γ [36,37]. However, such findings 
could be the result of antipsychotic drug treatment, poor 
diet or unhealthy life styles, which are often associated 
with chronic stages of the disease [38].
In addition to the findings in brain tissues, numerous 
studies have reported peripheral circulatory and cellular 
pro­inflammatory abnormalities in schizophrenia patients 
[39]. A meta­analysis of cytokine alterations in schizo­
phrenia showed that molecules such as IL­1β, IL­6 and 
TGF­β may be state markers for acute exacerbations, 
whereas others, including IL­12, IFN­γ, TNF­α and soluble 
IL­2 receptor, may be trait markers [40]. By definition, 
state biomarkers can reflect the changing states or stages 
of disease and are therefore diagnostic biomarkers. Trait 
biomarkers are associated with underlying endopheno­
types, which can be used to predict the likelihood of 
developing disease. We carried out multiplex immuno­
assay analyses of serum from first­episode, anti­psychotic­
naive schizophrenia patients that resulted in identifica­
tion of a disease signature comprising several inflamma­
tion­related proteins [24,25] and many of these have been 
implicated previously in patients with autoimmune 
diseases [41,42]. Notably, there are studies suggesting 
that some of the clinical features of schizophrenia may be 
correlated with autoimmune processes [43]. Autoimmune 
mechanisms may play a role in the etiology of schizo­
phrenia, as shown by the observation of elevated levels of 
autoantibodies in blood, cerebrospinal fluid and post­
mortem brains in some schizophrenia patients [44].
Inflammation in the periphery can affect brain function 
via effects on the HPA axis. Previous studies have shown 
that an increase in pro­inflammatory cytokines can lead 
to altered HPA axis response [45,46]. Under normal 
conditions, corticotrophin releasing factor is released 
from the hypothalamus, causing adrenocorticotrophic 
hormone to be released from the pituitary and cortisol to 
be released from the adrenal cortex [47]. The increase in 
cortisol has a negative feedback effect on the HPA axis 
through the brain and pituitary [48] (Figure  1). This 
mechanism exerts its effects on neurotransmitter systems 
throughout the brain that can affect mood and behavior.
Recent studies have explored the possibility of using 
immunomodulatory drugs such as cyclooxygenase­2 
inhi bi tors for treatment of schizophrenia symptoms 
[49,50]. A greater improvement in negative symptoms 
was observed in early stage patients treated with ami­
sulpride plus celecoxib compared with those treated with 
amisulpride plus placebo [51]. It should be noted that 
these findings have not been universally accepted and 
require validation by testing in separate cohorts. How­
ever, it is envisaged that initial screening for patients with 
high inflammatory status could lead to improved out­
comes in similar studies. Aspirin given as adjuvant 
therapy to regular antipsychotic treatment was used to 
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reduce the symptoms associated with schizophrenia 
spectrum disorders [52].
Proteomic biomarkers related to neuroendocrine 
pathways
Recent studies have demonstrated impaired fasting glu­
cose tolerance, high insulin levels and insulin resistance 
in first episode, antipsychotic naive patients compared 
with healthy controls [8,53]. Hyperinsulinemia and insulin 
resistance have also been found in drug­free chronic 
schizophrenia patients [54,55]. Another study found 
significant hepatic insulin resistance in schizophrenia 
patients compared with controls using a hyperinsulinemic 
clamp method [56]. Proteomic profiling of stimulated 
peripheral blood cells showed altered levels of glycolytic 
enzymes, the glucose transporter 1 and insulin receptor 
in cells from first episode antipsychotic­naive schizo­
phrenia patients compared with controls, suggesting an 
abnormality in glycolysis and other metabolic pathways 
after immune challenge [57]. In addition, we identified 
increased levels of circulating insulin­related molecules 
in first onset schizophrenia subjects, indicating hyper­
secretion from pancreatic beta cells [16]. This could have 
important implications since chronically elevated insulin 
levels can have deleterious effects on brain function [58]. 
High insulin levels have been associated with aberrant 
phosphorylation of filamentous proteins, increased brain 
inflammation and β­amyloid plaque deposition [59,60]. 
Hyperinsulinemia is also known to perturb the function 
of neurotransmitter systems [61] and has been shown to 
have direct effects on hippocampal synaptic plasticity 
[62]. Moreover, recent imaging studies have shown that 
patients with impaired glucose tolerance need more 
insulin than healthy subjects for maximal brain glucose 
uptake [63]. Therefore, using proteomic biomarkers to 
substratify patients with metabolic syndrome at early 
onset of schizophrenia may facilitate early intervention 
using add­on treatment with antidiabetic agents.
Insulin is co­secreted from pancreatic beta cells with 
other bioactive peptides, prohormone converting enzymes 
and accessory proteins in response to elevations in blood 
glucose [64]. Given that most of these cellular activities 
are regulated via insulin signaling, it is likely that 
increased pancreatic beta cell output would affect secre­
tion of hormones and bioactive peptides from other cells 
throughout the diffuse neuroendocrine system (Figure 2). 
Consistent with this, increased cortisol secretion and 
activation of the HPA axis has been identified as a risk 
factor for schizophrenia in adolescents [65]. Another 
study showed gender­specific changes in the hormones 
prolactin, estradiol and testosterone, in first­onset 
schizo phrenia patients [66]. There are also reports of 
increased levels of arginine vasopressin in schizophrenia 
patients, which can have profound effects on water 
excretion [67]. Other studies have also linked abnormal 
arginine vasopressin levels to changes in mood and 
behavior [68], which may be mediated through effects on 
adrenocorticotrophic hormone and cortisol [69].
We carried out multiplex immunoassay analyses of sera 
from first­ and recent­onset schizophrenia patients and 
found increased levels of insulin, chromogranin A, 
pancreatic polypeptide, prolactin, progesterone and 
cortisol, and decreased levels of growth hormone, com­
pared with controls [17]. More recent studies found 
decreased serum levels of thyroxine, tri­iodothyronine 
and thyroid stimulating hormone in schizophrenia 
patients [70]. Since many hormones are influenced by 
ultradian or circadian rhythms, it is likely that the mole­
cules measured here are co­regulated as part of an 
oscillatory feedforward­feedback relationship between 
the pancreatic beta cells, the pituitary and other neuro­
endocrine components of the HPA and gonadal systems. 
For instance, high insulin levels have been linked to 
increased prolactin secretion [71] and impaired pulsatile 
release of growth hormone [72]. Another study found 
increased cortisol levels in an antipsychotic­free cohort 
of schizophrenia patients [73]. Interestingly, initial 
cortisol levels correlated with negative symptom severity 
and reduction of negative symptoms was related to 
altered cortisol levels [74]. The changes in chromogranin 
Figure 1. Potential effects of immune system activation of 
the hypothalamic-pituitary-adrenal axis and brain function. 
ACTH, adrenocorticotrophic hormone; CRF, corticotrophin releasing 
factor; DA, dopamine; IL, interleukin; NE, norepinephrine; TNF, tumor 
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A levels are of interest as this precursor protein under­
goes proteolytic processing to produce smaller functional 
peptides, including vasostatins I and II [75]. This may be 
important as these peptides regulate the vasodilatation 
response, which is known to be altered in some schizo­
phrenia patients [76]. Chromogranin A is also processed 
to form the peptides catestatin and pancreastatin, which 
inhibit secretion from catecholaminergic adrenal chro­
ma ffin cells [77] and pancreatic beta cells [78], respect­
ively. This may also be relevant for schizophrenia, 
considering the hypothesized role of perturbed catechol­
amine [79] and insulin signaling pathways [54,55]. 
Further work is warranted to determine whether other 
proteins that are secreted via the diffuse neuroendocrine 
system also have a role in schizophrenia. This could lead 
to additional insights into the link between central 
nervous system perturbations and whole body metabolic 
homeostatic mechanisms.
The finding that high levels of circulating insulin­
related peptides occur in schizophrenia suggests that 
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drugs that improve insulin receptor signaling may offer a 
novel treatment approach. However, antipsychotic drugs 
are notorious for inducing metabolic side effects such as 
insulin resistance and weight gain, and the degree of 
weight gain appears to be linked to therapeutic efficacy. 
In one study, alterations in body weight, blood glucose 
and leptin levels were associated with improvement in 
positive and negative symptoms [80]. Also, changes in 
levels of serum lipids have been correlated with clinical 
response to atypical antipsychotic treatment [81]. Thera­
peutic strategies that target the underlying metabolic 
dysfunction may provide an effective alternative to 
treating the traditional neurotransmitter­related end­
point of the disorder. The insulin­sensitizing agents met­
formin and rosiglitazone have been used to correct the 
antipsychotic­induced insulin resistance typically asso­
ciated with this class of drugs, without compromising the 
psychotropic benefits [82]. We suggest that in future 
studies testing the effects of such add­on treatments, 
biomarkers associated with perturbed insulin signaling 
could be used for patient stratification and for monitoring 
treatment responses or side effects.
Similar strategies are also being tested for treatment of 
memory deficits in patients with Alzheimer’s disease. 
Clinical trials are focusing on the use of insulin­sensi­
tizing agents such as rosiglitazone and pioglitazone as an 
alternative approach to enhance cognition [83]. One 
group conducted a 6­month, randomized, open­con­
trolled trial in patients with mild Alzheimer’s disease 
accom panied by type  2 diabetes [84]. Patients who 
received pioglitazone showed improved cognition and 
increased regional cerebral blood flow, compared with 
those who received placebo. In addition, other hormones 
have been targeted as a novel means of treating schizo­
phrenia. For example, the adrenal steroid dehydro epi­
andro sterone (DHEA) has been used as an add­on 
therapy in medicated schizophrenia patients, which 
resulted in a significant improvement in negative, de­
pressive and anxiety symptoms [85]. Notably, improve­
ments in some aspects of psychological function have 
also been demonstrated following DHEA treatment of 
patients with Addison’s disease [86]. Interestingly, this 
treatment also led to improvements in self­esteem and 
mood, indicating their potential utility in psychiatric 
indica tions. Also, testing of the selective estrogen 
receptor modulator raloxifene has been shown to reduce 
symptoms in postmenopausal schizophrenia women with 
prominent negative manifestations [87].
Identification of proteomic biomarkers for 
prediction of treatment response
Biomarkers that can predict response of schizophrenia 
subjects prior to treatment would be of major benefit to 
the patients themselves, as well as to prescribing 
physicians, clinical scientists, pharmaceutical companies 
conducting clinical trials and the healthcare services in 
general. Previous schizophrenia studies have shown that 
a combination of variants in the histamine  2 receptor 
gene can predict response to clozapine treatment in 76% 
of cases [88]. There is also evidence that genetic variants 
in dopamine receptors, serotonin receptors and proteins 
such as catechol­O­methyltransferase, which are involved 
in drug metabolism pathways and neurotransmitter 
turnover, can affect clinical response and development of 
side effects [89]. Another study showed that physical 
parameters such as waist circumference, body mass 
index, triglycerides and high­density lipoproteins could 
be used to predict the antipsychotic­induced develop­
ment of metabolic syndrome or other insulin resistant 
states with good sensitivity and specificity [90].
Proteomic studies have shown that schizophrenia 
patients with higher levels of serum prolactin have a 
better outcome after 5  years of antipsychotic treatment 
[91]. We carried out multiplex immunoassay profiling of 
serum and found that the levels of seven proteins (IL­16, 
fatty acid binding protein, ferritin, C­reactive protein, 
myoglobin, prolactin and complement factor H) could 
predict improvement in positive symptoms, and two 
proteins (matrix metalloproteinase  2 and insulin) could 
be used for prediction of improved negative symptoms in 
first­onset schizophrenia patients after antipsychotic 
treatment [92]. In addition, we found that reduced levels 
of insulin and leptin and increased levels of TGF­β were 
indicative of impending relapse in the same anti­
psychotic­treated patients.
Other studies have shown that a number of serum 
molecules are altered in response to antipsychotic treat­
ment that have associations with inflammatory [40] and 
hormonal [92,93] pathways. Thus, many of these could be 
used as potential biomarkers of efficacy or side­effect 
response. Further studies investigating these molecules 
may lead to molecular tests that can aid in the identi­
fication of patients who are likely to respond to specific 
antipsychotic treatments and who may benefit from 
adjunct therapies targeting either inflammatory or meta­
bolic pathways. This could also offer the chance for 
clinicians to take appropriate action such as patient 
assess ment, counseling and re­adjusting medications 
accord ing to experimentally determined biomarker pro­
files. In some cases this could mean switching patients to 
a different antipsychotic with different efficacy or side­
effect profile.
Conclusions
The studies presented here indicate considerable progress 
in using proteomic­based biomarkers for the ultimate 
goal of improving care of schizophrenia patients. We also 
suggest that there is critical need for integrating data 
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from a number of different molecular profiling methods 
such as proteomic, transcriptomic and metabonomic 
platforms. This could lead to a more integrative view of 
the perturbed biological pathways in schizophrenia 
through a systems biology approach. Biomarker finger­
prints have been identified in serum samples of first­
onset schizophrenia patients; this indicates that this 
condi tion may comprise different subtypes at the mole­
cular level, which could potentially lead to earlier and 
more targeted intervention, reducing disease progression. 
Many patients have patterns of circulating molecules 
suggestive of dysfunctional immune or metabolic sys­
tems, with elevated levels of inflammatory cytokines or 
metabolic abnormalities such as high insulin levels or 
insulin resistance. However, it is possible that even these 
are not distinct subtypes but may be related to the same 
underlying phenomena. Nevertheless, better classifica­
tion of patients based on such molecular profiles would 
enable stratification prior to treatment. This would entail 
adopting an endophenotype approach by using specific 
readouts such as inflammation or insulin resistance as 
end­point measurements. Furthermore, a molecular test 
that recognizes such subtypes may be used for identifying 
patients who are most likely to respond to particular treat­
ments. This could lead to more effective treatments with 
fewer side effects. For example, patients with high insulin 
levels could be administered insulin sensitizing agents as 
an adjunct therapy with standard antipsychotics, aiming to 
minimize metabolic side effects while maintaining 
improved psychotherapeutic responses (Figure  3). This 
approach has already shown promise in clinical studies 
that have used metformin or rosiglitazone to minimize 
the weight gain in response to treatment with typical and 
atypical antipsychotics [82,94].
Thus far, none of the longitudinal studies that has 
targeted the inflammatory or metabolic components in 
schizo phrenia has incorporated the use of biomarkers to 
stratify patient populations either prior to or during 
clinical trials. Therefore, it will be necessary to explore 
the relationship between alterations that appear to be 
intrinsic to schizophrenia etiology and to assess the 
response to currently used antipsychotics. Furthermore, 
the increased use of longitudinal studies will help to 
address one of the key requirements of proteomic­based 
biomarkers, which is the need for stability over time. This 
could also be assessed in controls as a means of 
identifying factors that can affect biomarker readouts.
The categorization of patients based on proteomic 
biomarker profiles for optimized treatment is a form of 
personalized medicine. This important paradigm has 
probably been best exemplified in the field of breast 
cancer, where the presence of the human epidermal 
growth factor receptor  2 (HER­2) helps to select those 
patients who will benefit from treatment with Herceptin 
[95]. Such efforts will lead to novel therapeutic targets for 
drug development and to the individualization of 
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treat ment, maximizing the likelihood of positive thera­
peutic outcomes. In the case of schizophrenia it also 
offers the opportunity to support the personalized 
medicine vision by de­convoluting the complexity of the 
disease from superficial symptom characterization to an 
objective biological understanding. In particular, 
proteomic methods could be used to determine whether 
patients can be divided into subgroups that show distinct 
changes in either immune or metabolic pathways, as 
opposed to mixed changes in both pathways. This would 
help to address the hypothesis that schizophrenia is a 
hetero geneous condition comprising distinct subtypes 
and could also lead to the development of much­needed 
novel therapeutic approaches for schizophrenia that 
target the affected pathways.
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